A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia.

Trial Profile

A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2014

At a glance

  • Drugs MK 8998 (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 22 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2010 Actual patient number (216) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top